Timothy Rolph - Sep 13, 2022 Form 4/A - Amendment Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Scientific Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Sep 13, 2022
Transactions value $
-$592,950
Form type
4/A - Amendment
Date filed
10/27/2022, 09:23 PM
Date Of Original Report
Sep 15, 2022
Previous filing
Sep 13, 2022
Next filing
Oct 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $63.6K +10K +4.06% $6.36* 256K Sep 13, 2022 Direct F1, F2
transaction AKRO Common Stock Sale -$657K -22.5K -8.78% $29.18 234K Sep 13, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -10K -13.74% $0.00 62.8K Sep 13, 2022 Common Stock 10K $6.36 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 15, 2022, the reporting person filed a Form 4 which inadvertently omitted the exercise of 10,000 options by the reporting person. The shares of Common Stock underlying those options were subsequently sold pursuant to a Rule 10b5-1 trading plan as reported in the original Form 4. This amendment to the original Form 4 is being filed solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock.
F2 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2021, previously adopted by the reporting person.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4 This option shall vest and become exercisable in 48 equal monthly installments, commencing on January 1, 2019.